Literature DB >> 21053525

Cervical cancer and the role of lymph node staging cons sentinel concept.

Hermann Hertel1.   

Abstract

OBJECTIVE: To determine whether the current standard of cervical cancer staging is sentinel lymph node biopsy.
METHOD: Review of the literature focusing on the significance of the sentinel node concept in patients with cervical cancer. Because of the data on the significance of the intraoperative histopathological assessment of sentinel lymph nodes, the role of micrometastasis in lymph nodes, and the standards of procedure, the sentinel procedure were analyzed. RESULT: Sentinel lymph node biopsy alone is currently not a routine procedure for cervical cancer staging. This procedure should be performed only by specialized centers in a study setting. More data on its oncological safety are needed.

Entities:  

Mesh:

Year:  2010        PMID: 21053525     DOI: 10.1111/igc.0b013e3181f7f52b

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  3 in total

1.  Definition of compartment based radical surgery in uterine cancer-part I: therapeutic pelvic and periaortic lymphadenectomy by Michael höckel translated to robotic surgery.

Authors:  Rainer Kimmig; Antonella Iannaccone; Paul Buderath; Bahriye Aktas; Pauline Wimberger; Martin Heubner
Journal:  ISRN Obstet Gynecol       Date:  2013-03-25

2.  Comparative assessment of lymph node micrometastasis in cervical, endometrial and vulvar cancer: insights on the real time qRT-PCR approach versus immunohistochemistry, employing dual molecular markers.

Authors:  Kalliopi I Pappa; Alexandros Rodolakis; Ioanna Christodoulou; Maria Gazouli; Sofia Markaki; Aris Antsaklis; Nicholas P Anagnou
Journal:  Biomed Res Int       Date:  2014-01-02       Impact factor: 3.411

3.  Preoperative nomogram for the identification of lymph node metastasis in early cervical cancer.

Authors:  D-Y Kim; S-H Shim; S-O Kim; S-W Lee; J-Y Park; D-S Suh; J-H Kim; Y-M Kim; Y-T Kim; J-H Nam
Journal:  Br J Cancer       Date:  2013-11-14       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.